编号：2022-008 1 / 3 证券代码：301206 证券简称：三元生物 山东三元生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |---------------------|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------| | | √ 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 □ | 业绩说明会 | | 投资者关系活动类 别 | □ 新闻发布会 □ | 路演活动 | | | □ 现场参观 √ | 电话会议 | | | □ 其他： | （请文字说明其他活动内容） | | 参与单位名称 | | 华商基金郭鹏；中金宗旭豪、钱凌霄、张毓 | | 及人员姓名 | | | | 时间 | 2022 年 9 月 20 日 | 08:30-09:30 | | 地点 | 网络会 ...

证券代码：301206 证券简称：三元生物 编号：2022-007 山东三元生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------------|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | √ 特定对象调研 | □分析师会议 | | | □媒体采访 | □业绩说明会 | | 投资者关系活动类 | □新闻发布会 | □路演活动 | | 别 | □现场参观 √ | 电话会议 | | | □其他： | （请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | | 摩根高云；中金宗旭豪、候一林、夏雪、舒嫣然 | | 时间 | 2022 年 8 月 26 日 | 14:30-16:00 | ...

Financial Performance - Revenue for Q3 2022 was CNY 106,086,181.83, a decrease of 79.54% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2022 was CNY 31,976,384.64, down 83.83% year-on-year[4] - Basic earnings per share for Q3 2022 was CNY 0.16, a decline of 91.84% compared to the previous year[4] - Operating income for the first nine months of 2022 was CNY 563,363,651.68, down 56.84% year-on-year due to increased market competition[10] - The company reported total revenue of CNY 563,363,651.68 for the current period, down from CNY 1,305,360,240.59 in the previous period, indicating a decline of approximately 56.7%[26] - The net profit for Q3 2022 was CNY 151,155,941.78, a decrease of 65.7% compared to CNY 440,682,536.29 in the same period last year[28] - Operating profit for Q3 2022 was CNY 169,888,387.28, a decline of 66.7% from CNY 510,138,452.87 in Q3 2021[28] - The total comprehensive income for Q3 2022 was CNY 151,155,941.78, down from CNY 440,682,536.29 in the same quarter last year[28] Assets and Liabilities - Total assets at the end of Q3 2022 reached CNY 4,798,187,821.59, an increase of 193.62% from the end of the previous year[4] - As of September 30, 2022, total assets amounted to CNY 4,798,187,821.59, a significant increase from CNY 1,634,157,434.85 at the beginning of the year[22] - The total liabilities decreased to CNY 189,942,474.74 from CNY 588,828,870.18, a reduction of approximately 67.8%[24] Cash Flow - Cash flow from operating activities for the first nine months of 2022 was CNY 90,426,851.62, a decrease of 82.62% year-on-year[4] - The net cash flow from operating activities for the first nine months of 2022 was ¥90,426,851.62, a decrease of 82.62% compared to the same period last year, primarily due to intensified market competition and a decline in sales prices and volumes[12] - The net cash flow from investing activities for the first nine months of 2022 was -¥3,282,248,061.08, an increase of 892.61% year-on-year, mainly due to the purchase of large bank deposits during the reporting period[12] - The net cash flow from financing activities for the first nine months of 2022 was ¥3,417,536,634.32, an increase of 53,306.88% compared to the same period last year, primarily due to funds raised from a public offering[12] - Cash flow from operating activities generated a net inflow of CNY 90,426,851.62, significantly lower than CNY 520,410,877.71 in the previous year[30] - Investment activities resulted in a net cash outflow of CNY 3,282,248,061.08, compared to a smaller outflow of CNY 330,668,081.12 in the previous year[30] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,514, with no preferred shareholders having restored voting rights[14] - The largest shareholder, Nie Zaijian, holds 45.94% of the shares, amounting to 92,946,000 shares[14] - The second-largest shareholder, Shandong Luxin Qisheng Investment Management Co., holds 12.25% of the shares, totaling 24,780,000 shares[14] - The company has a total of 154,353,406 restricted shares, with 2,609,206 shares released during the reporting period[17] - The company has no knowledge of any related party relationships among the top ten shareholders[15] - The company has not disclosed any information regarding the participation of the top ten shareholders in margin trading[15] - The company plans to release restricted shares on specific dates, with the earliest being February 10, 2023, for several shareholders[16] Research and Development - Research and development expenses for the first nine months of 2022 amounted to CNY 31,870,190.36, a decrease of 34.44% compared to the previous year[10] - Research and development expenses amounted to CNY 31,870,190.36, down 34.5% from CNY 48,614,684.08 year-over-year[28] Certification and Auditing - The company obtained AEO Advanced Certification on September 30, 2022, which enhances its customs clearance efficiency internationally[20] - The company changed its external auditor to Dahua Certified Public Accountants for the 2022 fiscal year, reflecting a strategic shift in its auditing needs[19] Inventory and Receivables - Accounts receivable decreased significantly to CNY 33,583,700.39 from CNY 141,359,628.59, representing a reduction of approximately 76.3%[22] - Inventory levels were reported at CNY 73,203,380.23, down from CNY 112,157,402.58, indicating a decrease of about 34.7%[23] Capital Changes - The company completed a capital increase, raising its total share capital from 134,883,800 shares to 202,325,700 shares, a 49.9% increase[18] Investment Income - Investment income for the first nine months of 2022 was CNY 60,094,512.56, an increase of 85582.95% year-on-year due to interest from bank large-denomination certificates[10] - The company received CNY 850,000,000.00 from investment recoveries during the reporting period[30]

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 15%[15]. - The gross profit margin for the first half of 2022 was 35%, compared to 30% in the same period last year[15]. - The company's operating revenue for the reporting period was ¥457,277,469.85, a decrease of 41.89% compared to the same period last year[24]. - The net profit attributable to shareholders was ¥119,179,557.14, down 50.93% year-on-year[24]. - The net profit after deducting non-recurring gains and losses was ¥76,779,672.40, representing a decline of 68.38% compared to the previous year[24]. - The net cash flow from operating activities was ¥32,357,268.57, a significant drop of 88.16% from the same period last year[24]. - The company's revenue for the reporting period was approximately ¥457.28 million, a decrease of 41.89% compared to ¥786.89 million in the same period last year, primarily due to a decline in sales prices and volumes[51]. - The company reported a net cash inflow from financing activities of approximately ¥3.42 billion, a significant increase of 53,332.55% due to funds raised from public offerings[51]. - The company's comprehensive gross margin for 2020, 2021, and the first half of 2022 was 42.27%, 41.99%, and 21.30% respectively, indicating a significant decline in profitability due to increased market competition and rising labor costs[86]. - The company reported a significant increase in revenue for the first half of 2022, achieving a total of 1.5 billion RMB, representing a year-over-year growth of 25%[108]. - The company reported a significant increase in revenue for the first half of 2022, achieving a total of 500 million RMB, representing a 20% year-over-year growth[115]. Research and Development - The company plans to invest RMB 100 million in R&D for new product development in the next fiscal year[15]. - Research and development expenses were ¥22.19 million, down 22.33% from ¥28.58 million, mainly due to the completion of certain R&D projects[51]. - The company is focusing on R&D in synthetic biology and has established a wholly-owned subsidiary to enhance its technological capabilities in green products[46]. - The company is investing heavily in R&D, with a budget increase of 30% for new technology development in 2022[108]. - New product development efforts are underway, with an investment of 5 million RMB allocated for research and development in innovative biotechnology solutions[109]. - The company aims to enhance its research and development capabilities to innovate and improve its product offerings[194]. Market Expansion and Strategy - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 10% market share by 2025[15]. - The company plans to expand its market presence by entering two new provinces in China by the end of 2022, aiming for a 25% increase in market share[109]. - Market expansion plans include entering two new provinces, aiming for a 10% market share in these regions by 2023[108]. - The company is considering strategic acquisitions to enhance its product portfolio, with a target of completing at least one acquisition by the end of 2022[108]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence[15]. Operational Efficiency - The conversion rate of raw materials to end products improved to 85% in the first half of 2022[13]. - The company focuses on a "production based on sales" model, ensuring timely delivery of products according to customer orders[35]. - The company maintains a reasonable inventory level, balancing production with market demand to optimize operational efficiency[34]. - The company has set a target to reduce operational costs by 15% over the next year through efficiency improvements[108]. - The company aims to reduce operational costs by 15% through efficiency improvements in the supply chain[115]. Financial Management and Shareholder Returns - No cash dividends or stock bonuses will be distributed for the current fiscal year[5]. - The company plans to implement a share repurchase program, with a total amount not exceeding 20% of the previous year's audited net profit attributable to shareholders[110]. - The company will prioritize measures such as stock repurchase and increasing holdings by controlling shareholders to stabilize the stock price[110]. - The company will ensure compliance with relevant laws and regulations during the share increase process[111]. - The company has committed to a profit distribution mechanism post-IPO, ensuring a cash dividend policy to protect investor rights[114]. Risks and Challenges - The company faces risks related to supply chain disruptions and has implemented measures to mitigate these risks[4]. - The company faced risks from intensified market competition in the erythritol industry, which could affect pricing and market share if not addressed through capacity expansion and technological upgrades[79]. - The ongoing COVID-19 pandemic has created uncertainties that could negatively impact the company's operational performance, with a focus on maintaining safety and production management[85]. - The company is facing risks of unsustainable high gross margins and rapid revenue growth due to intensified market competition and unfavorable demand changes[86]. - The company acknowledges the existence of internal and external risks that may impact future profits, and investors are advised to consider these risks in their investment decisions[113]. Sustainability and Compliance - The company emphasizes environmental protection and has implemented an ISO14001 environmental management system[100]. - The extraction process for erythritol is a green and environmentally friendly technology, enhancing yield and reducing production costs[106]. - The company adheres to legal regulations and aims for sustainable development while ensuring economic and social benefits[101]. - The management emphasized the importance of compliance and transparency in all financial disclosures to maintain investor trust[115]. Shareholder Structure and Governance - The company has a total of 26,531 shareholders at the end of the reporting period[155]. - The largest shareholder, Nie Zaijian, holds 45.94% of the shares, totaling 92,946,000 shares, with an increase of 30,982,000 shares during the reporting period[156]. - The company’s shareholder structure includes significant holdings by domestic natural persons and institutional investors[151]. - The company has not conducted any repurchase transactions among the top 10 shareholders during the reporting period[158]. - The report indicates that there are no differences in voting rights among shareholders[158].

Dividend and Capital Management - The company plans to distribute a cash dividend of 10.00 RMB per 10 shares to all shareholders, based on a total of 134,883,800 shares[4]. - The company will increase its capital reserve by converting 5 shares for every 10 shares held by shareholders[4]. - The company plans to distribute cash dividends amounting to at least 30% of the average distributable profit over the next three years, ensuring stable returns for shareholders[159]. - A cash dividend of 10.00 CNY per 10 shares (including tax) will be distributed, totaling 134,883,800.00 CNY, with no stock dividends issued[162]. - The cash dividend represents 100% of the total profit distribution, adhering to the minimum requirement of 20% for companies in a growth phase[161]. - The company plans to increase its total share capital by 67,441,900 shares through a capital reserve conversion, resulting in a new total of 202,325,700 shares[162]. Financial Performance - The company's operating revenue for 2021 was ¥1,675,320,034.94, representing a 113.91% increase compared to ¥783,182,230.09 in 2020[18]. - The net profit attributable to shareholders for 2021 was ¥535,415,008.89, a 130.21% increase from ¥232,572,771.07 in 2020[18]. - The net cash flow from operating activities reached ¥642,075,356.24, marking a 195.39% increase compared to ¥217,367,948.72 in 2020[18]. - The basic earnings per share for 2021 was ¥5.29, up 130.00% from ¥2.30 in 2020[18]. - The total assets at the end of 2021 amounted to ¥1,634,157,434.85, a 109.13% increase from ¥781,390,501.72 at the end of 2020[18]. - The company reported a significant increase in fixed assets, totaling CNY 413,339,585.50, which decreased as a percentage of total assets from 36.09% to 25.29% due to ongoing construction projects being completed[84]. - The company achieved a revenue of CNY 1,675.32 million in 2021, representing a year-on-year growth of 113.91%[57]. - Net profit attributable to shareholders reached CNY 535.42 million, marking a 130.21% increase compared to the previous year[57]. Research and Development - The company highlights its focus on research and development of functional sugars and food additives, which are critical to its product offerings[12]. - Research and development expenses increased by 94.46% to ¥59,001,226.95, driven by more projects and higher material and labor costs[75]. - The number of R&D personnel rose to 49, a 32.43% increase from 37 in the previous year[77]. - The company is currently developing multiple new products, including the enzyme method for preparing Reb M and the preparation technology for allulose[76]. - The company plans to enhance the purity of Reb M to ≥98% through advanced refining techniques[76]. - The company has signed agreements with research institutions to develop new sweeteners, enhancing its R&D capabilities and product offerings[59]. Market and Competitive Position - The company is the largest producer of erythritol globally, with erythritol and its blended sugars accounting for 97.97% of total revenue during the reporting period[32]. - The market for functional foods is rapidly growing in China, driven by increasing health awareness and changing consumer preferences, creating a strong demand for high-value products like erythritol[30]. - The adult overweight rate in China is 34.3%, and the obesity rate is 16.4%, highlighting a significant market opportunity for sugar substitutes like erythritol[41]. - The company has experienced significant growth in user data and market share, driven by increased demand for its products[29]. - The company is actively exploring potential mergers and acquisitions to enhance its market position and expand its operational capabilities[29]. - The company plans to continue expanding its product offerings in the erythritol and compound sugar products sector, focusing on R&D and market penetration[29]. Risk Management - The company acknowledges potential risks in future operations and outlines corresponding mitigation strategies in the management discussion section[4]. - The company faces risks from increasing market competition and potential price declines in erythritol due to new entrants and capacity expansions[99]. - The company is addressing the risk of raw material price increases, particularly corn, which significantly affects production costs[102]. - The company plans to enhance its risk resistance capabilities by adjusting strategies based on market conditions, including price adjustments and purchasing export credit insurance[103]. Corporate Governance - The board of directors has confirmed that all members attended the meeting to review the annual report, ensuring collective accountability[4]. - The company has established a sound corporate governance structure, including a board of directors and supervisory board, operating independently from controlling shareholders[126]. - The company has a dedicated human resources management system, ensuring that all employees are under independent contracts[123]. - The company has maintained a stable management team with no changes in directors or senior management during the reporting period[131]. - The company has a diverse board with members holding expertise in various fields, including engineering, finance, and management[135]. Compliance and Transparency - The report emphasizes the importance of accurate financial reporting and the responsibility of management to ensure completeness and truthfulness[3]. - The company has committed to transparency by making all relevant documents available for public inspection, including financial statements and audit reports[9]. - The company emphasizes social responsibility, focusing on economic and social benefits, and adheres to national laws and regulations[170]. - The company ensures investor rights protection by providing timely, accurate, and complete information disclosure, maintaining fairness and transparency[171]. - The company complies with labor laws, providing employees with contracts and social insurance, while focusing on their safety and health[171]. Operational Efficiency - The company employs a "sales-driven production" model, ensuring timely delivery of products based on customer orders[36]. - The company’s procurement strategy is based on a "production-based ordering" model, allowing for efficient inventory management and cost control[34]. - The integration of ERP and production automation systems has improved operational efficiency and responsiveness to customer needs[53]. - The company has implemented a comprehensive quality management system, achieving multiple international certifications including ISO9001:2015 and FDA approval[55]. Future Outlook - The company provided guidance for the next fiscal year, projecting a revenue growth of 25% and aiming to reach 1.875 billion RMB[178]. - The company plans to invest in a new project to produce 50,000 tons of erythritol, which is expected to significantly enhance profitability and market position[58]. - The company plans to enhance its market presence through strategic investments and partnerships in the biotechnology industry[134]. - The company plans to implement a stock repurchase program to stabilize its stock price, with a total repurchase amount not exceeding 20% of the previous year's audited net profit attributable to shareholders[181].

Revenue and Profitability - The company's revenue for Q1 2022 was ¥272,598,107.02, representing a 3.46% increase compared to ¥263,493,075.06 in the same period last year[3] - Net profit attributable to shareholders decreased by 9.64% to ¥62,765,994.16 from ¥69,465,064.33 year-on-year[3] - The net profit after deducting non-recurring gains and losses fell by 28.25% to ¥49,823,107.30 compared to ¥69,435,706.54 in the previous year[3] - Total operating revenue for Q1 2022 was CNY 272,598,107.02, an increase of 3.9% compared to CNY 263,493,075.06 in Q1 2021[19] - Net profit for Q1 2022 was CNY 62,765,994.16, a decrease of 9.7% from CNY 69,465,064.33 in Q1 2021[20] - Basic and diluted earnings per share for Q1 2022 were CNY 0.51, down from CNY 0.69 in Q1 2021[21] Cash Flow and Liquidity - The net cash flow from operating activities decreased significantly by 84.24% to ¥20,443,976.73 from ¥129,686,530.82 year-on-year[3] - The net cash flow from operating activities for Q1 2022 was ¥20,443,976.73, a decrease of 84.25% compared to ¥129,686,530.82 in Q1 2021[24] - Total cash inflow from operating activities was ¥312,922,891.80, while cash outflow was ¥292,478,915.07, resulting in a net increase of ¥9,443,976.73[24] - The ending balance of cash and cash equivalents was ¥267,134,010.23, compared to ¥141,186,753.95 at the end of Q1 2021, marking an increase of 89.38%[25] - The company received tax refunds amounting to ¥26,459,620.09, an increase from ¥17,947,944.83 in the previous year[24] Assets and Liabilities - Total assets increased by 213.32% to ¥5,120,094,004.66 from ¥1,634,157,434.85 at the end of the previous year[3] - Total liabilities for Q1 2022 were CNY 465,185,884.07, down from CNY 588,828,870.18 in Q1 2021[17] - Owner's equity totaled CNY 4,654,908,120.59 in Q1 2022, a substantial increase from CNY 1,045,328,564.67 in the same period last year[17] - Deferred income tax liabilities increased to CNY 25,228,040.35 in Q1 2022 from CNY 23,025,951.67 in Q1 2021[17] Investment and Expenditures - The company reported a significant increase in investment income due to enhanced fund management after receiving proceeds from the public offering[6] - The company invested ¥3,435,489,780.51 in various projects during the quarter, indicating a significant commitment to growth and expansion[24] - The company established a wholly-owned subsidiary, Sanyuan Biological Engineering Research (Tianjin) Co., Ltd., with an investment of RMB 5 million to enhance R&D capabilities[13] Shareholder Information - The total number of common shareholders at the end of the reporting period is 21,906[10] - The largest shareholder, Nie Zaijian, holds 45.94% of shares, totaling 61,964,000 shares[10] - The company raised a total of RMB 3,685,705,300 from the public offering of 33,721,000 shares at RMB 109.3 per share, with a net amount of RMB 3,546,644,640 after deducting issuance costs[12] Operating Costs and Expenses - Total operating costs for Q1 2022 were CNY 215,835,919.52, up 17.5% from CNY 183,703,681.92 in the same period last year[19] - Research and development expenses for Q1 2022 were CNY 10,219,983.55, a decrease of 11.7% compared to CNY 11,579,638.16 in Q1 2021[20] - The company experienced a 90.99% increase in cash paid for purchasing goods and services, attributed to a shift in payment methods due to rising raw material prices[7] - The cash paid for purchasing goods and services was ¥266,221,244.95, which is a substantial increase from ¥139,392,617.05 in Q1 2021[24] Audit and Reliability - The report for Q1 2022 was not audited, which may affect the reliability of the financial data presented[26]